Haleon Plc - ADR [HLN] vs Intra-Cellular [ITCI] Detailed Stock Comparison

Haleon Plc - ADR

NYSE
Loading...

Intra-Cellular Therapies Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Haleon Plc - ADR wins in 14 metrics, Intra-Cellular Therapies Inc. wins in 4 metrics, with 0 ties. Haleon Plc - ADR appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Haleon Plc - ADR Intra-Cellular Therapies Inc. Better
P/E Ratio (TTM) 18.72 -183.15 Haleon Plc - ADR
Price-to-Book Ratio 1.88 12.20 Haleon Plc - ADR
Debt-to-Equity Ratio 52.37 1.48 Intra-Cellular Therapies Inc.
PEG Ratio 15.42 507.19 Haleon Plc - ADR
EV/EBITDA 33.08 -112.19 Haleon Plc - ADR
Profit Margin (TTM) 15.11% -10.97% Haleon Plc - ADR
Operating Margin (TTM) 23.17% -14.66% Haleon Plc - ADR
EBITDA Margin (TTM) 23.17% N/A N/A
Return on Equity 10.27% -8.58% Haleon Plc - ADR
Return on Assets (TTM) 4.67% -6.96% Haleon Plc - ADR
Free Cash Flow (TTM) $2.22B $-73.50M Haleon Plc - ADR
Dividend Yield 1.63% N/A N/A
1-Year Return -16.01% 92.68% Intra-Cellular Therapies Inc.
Price-to-Sales Ratio (TTM) 3.78 20.63 Haleon Plc - ADR
Enterprise Value $122.54B $13.04B Haleon Plc - ADR
EV/Revenue Ratio 8.23 19.15 Haleon Plc - ADR
Gross Profit Margin (TTM) 55.38% 89.76% Intra-Cellular Therapies Inc.
Revenue per Share (TTM) $2 $7 Intra-Cellular Therapies Inc.
Earnings per Share (Diluted) $0.50 $-0.73 Haleon Plc - ADR
Beta (Stock Volatility) 0.33 0.46 Haleon Plc - ADR
Short % of Float 0.43% N/A N/A

Haleon Plc - ADR vs Intra-Cellular Therapies Inc. Stock Performance Analysis

Loading Price Chart...

HLN
ITCI

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Haleon Plc - ADR-0.66%2.02%1.23%-13.29%-7.73%-9.30%
Intra-Cellular Therapies Inc.0.00%N/AN/AN/AN/AN/A

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Haleon Plc - ADR-16.01%8.43%23.21%23.21%23.21%23.21%
Intra-Cellular Therapies Inc.92.68%104.13%700.67%449.92%632.61%632.61%

Performance & Financial Health Analysis: Haleon Plc - ADR vs Intra-Cellular Therapies Inc.

MetricHLNITCI
Market Information
Market Cap i$42.40B$14.05B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i6,594,2492,749,368
90 Day Avg. Volume i7,985,2302,309,509
Last Close$9.07$131.87
52 Week Range$8.65 - $11.28$64.09 - $131.98
% from 52W High-19.59%-0.08%
All-Time High$11.42 (Jun 02, 2025)$131.98 (Mar 31, 2025)
% from All-Time High-20.58%-0.08%
Growth Metrics
Quarterly Revenue Growth0.01%0.51%
Quarterly Earnings Growth0.86%0.51%
Financial Health
Profit Margin (TTM) i0.15%-0.11%
Operating Margin (TTM) i0.23%-0.15%
Return on Equity (TTM) i0.10%-0.09%
Debt to Equity (MRQ) i52.371.48
Cash & Liquidity
Book Value per Share (MRQ)$4.99$10.81
Cash per Share (MRQ)$0.15$9.42
Operating Cash Flow (TTM) i$3.56B$-73,177,000
Levered Free Cash Flow (TTM) i$1.89B$-63,549,624
Dividends
Last 12-Month Dividend Yield i1.63%N/A
Last 12-Month Dividend i$0.17N/A

Valuation & Enterprise Metrics Analysis: Haleon Plc - ADR vs Intra-Cellular Therapies Inc.

MetricHLN (Apr 24, 2026)ITCI (May 17, 2025)
Price Ratios
P/E Ratio (TTM) i18.72-183.15
Forward P/E i15.42507.19
PEG Ratio i15.42507.19
Price to Sales (TTM) i3.7820.63
Price to Book (MRQ) i1.8812.20
Market Capitalization
Market Capitalization i$42.40B$14.05B
Enterprise Value i$122.54B$13.04B
Enterprise Value Metrics
Enterprise to Revenue i8.2319.15
Enterprise to EBITDA i33.08-112.19
Risk & Other Metrics
Beta i0.330.46
Book Value per Share (MRQ) i$4.99$10.81

Financial Statements Comparison: Haleon Plc - ADR vs Intra-Cellular Therapies Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricHLN (2025)ITCI (2024)
Revenue/Sales i11.03B680.50M
Cost of Goods Sold i3.95B56.96M
COGS % of Revenue i35.8%8.4%
Gross Profit i7.08B623.54M
Gross Margin i64.2%91.6%
Research & Development i316.00M236.12M
Operating Income (EBIT) i2.41B-116.72M
Operating Margin i21.9%-17.2%
EBITDA i2.81B-116.21M
EBITDA Margin i25.5%-17.1%
Pre-Tax Income i2.15B-74.20M
Pre-Tax Income % of Revenue i19.5%-10.9%
Income Tax i472.00M473,000
Income Tax % of Revenue i4.3%0.1%
Net Income (Profit) i1.68B-74.68M
Profit Margin i15.2%-11.0%

Balance Sheet & Liquidity Metrics

MetricHLN (2025)ITCI (2024)
Cash & Equivalents i1.26B306.95M
Total Current Assets i4.55B1.31B
Total Current Assets % of Revenue i41.3%192.1%
Total Current Liabilities i4.93B205.70M
Total Current Liabilities % of Revenue i44.7%30.2%
Long-Term Debt i7.75B12.75M
Long-Term Debt % of Revenue i70.2%1.9%
Total Shareholders Equity i16.48B1.15B
Retained Earnings i27.85B-1.69B
Retained Earnings % of Revenue i252.5%-248.6%
Property, Plant & Equipment i1.00M14.90M

Cash Flow Statement Comparison

MetricHLN (2025)ITCI (2024)
Operating Cash Flow i2.19B-63.27M
Operating Cash Flow % of Revenue i19.8%-9.3%
Capital Expenditures i-322.00M-322,000
Free Cash Flow i2.22B-73.50M
FCF Margin i20.1%-10.8%
Debt Repayment i-1.35BN/A
Common Stock Repurchase i-654.00MN/A

Short Interest & Institutional Ownership Analysis

MetricHLNITCI
Shares Short i19.28MN/A
Short Ratio i2.14N/A
Short % of Float i0.43%N/A
Shares Outstanding i8.91B106.24M
Float Shares i8.86B104.82M
% Held by Insiders i0.01%2.48%
% Held by Institutions i12.74%96.45%
% Held by Public i87.25%1.07%

Dividend Analysis & Yield Comparison: Haleon Plc - ADR vs Intra-Cellular Therapies Inc.

MetricHLNITCI
Last 12-Month Dividend i$0.17N/A
Last 12-Month Dividend Yield i1.63%N/A
3-Year Avg Annual Dividend i$0.11N/A
3-Year Avg Dividend Yield i0.91%N/A
3-Year Total Dividends i$0.34N/A
Ex-Dividend DateApr 25, 2025N/A